Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899744 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL2905551 | 0.91 | SMN1; SMN2 (0.51) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL11336172 | 0.91 | SMN1; SMN2 (0.51) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL5350233 | 0.81 | MAPT (0.49) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL10968477 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL2900787 | 0.74 | MAPT (0.53) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL2900788 | 0.74 | MAPT (0.53) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL30067431 | 0.73 | MAPT (0.43) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL5347343 | 0.73 | MAPT (0.41) | ALDH1A1MAPTKMT2AMEN1NPSR1 | |
| SCHEMBL6860117 | 0.72 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-01-23 | — | — | US | disclosed |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2018-07-26 | — | — | US | disclosed |
| US-9957246-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
| US-5104985-A | Rearrangement in the presence of an alkali metal bis (tris-lower alkyl silyl)amide | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0193132-B1 | LABDAN-DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4963537-A | REDUCE INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4851397-A | LOWERING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4771049-A | REDUCING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1988-09-13 | — | — | US | disclosed |
| US-4677103-A | REDUCING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-30 | — | — | US | disclosed |
| US-4639443-A | INTRAOCULAR PRESSURE REDUCTION | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2229/4885MAPT 816/4885KMT2A 1832/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | ALDH1A1 2452/4885MAPT 706/4885KMT2A 1787/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2405/4885MAPT 917/4885KMT2A 1714/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 2229/4885MAPT 816/4885KMT2A 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.